Search results for "Angiotensin"

showing 10 items of 396 documents

Do genetic polymorphisms in angiotensin converting enzyme 2 (ACE2) gene play a role in coronavirus disease 2019 (COVID-19)?

2020

Abstract Although some demographic, clinical and environmental factors have been associated with a higher risk of developing coronavirus disease 2019 (COVID-19) and progressing towards severe disease, altogether these variables do not completely account for the different clinical presentations observed in patients with comparable baseline risk, whereby some subjects may remain totally asymptomatic, whilst others develop a very aggressive illness. Some predisposing genetic backgrounds can hence potentially explain the broad inter-individual variation of disease susceptibility and/or severity. It has been now clearly established that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2…

0301 basic medicinereceptorClinical BiochemistryPopulationPneumonia ViralAdipose tissueInflammationPeptidyl-Dipeptidase AAsymptomaticViruspolymorphism03 medical and health sciencesBetacoronavirus0302 clinical medicineProtein DomainsFibrosismedicineHumans030212 general & internal medicineeducationGenePandemicseducation.field_of_studyPolymorphism Geneticbusiness.industrySARS-CoV-2Biochemistry (medical)COVID-19General Medicineangiotensinmedicine.diseaseenzyme030104 developmental biologyCOVID-19 angiotensin enzyme polymorphism receptorImmunologyAngiotensin-converting enzyme 2Spike Glycoprotein CoronavirusReceptors VirusAngiotensin-Converting Enzyme 2medicine.symptombusinessCoronavirus InfectionsProtein Binding
researchProduct

Studies to Elucidate the Mechanism of Cardio Protective and Hypotensive Activities of Anogeissus acuminata (Roxb. ex DC.) in Rodents

2020

Anogeissus acuminata (Roxb. ex DC.) is a folkloric medicinal plant in Asia

1Pharmaceutical Scienceacute myocardial infarction 3030204 cardiovascular system & hematologyPharmacologyCreatineAnalytical ChemistryNitric oxidelcsh:QD241-44103 medical and health scienceschemistry.chemical_compound0302 clinical medicinevasorelaxant 4lcsh:Organic chemistryIn vivoDrug DiscoveryRenin–angiotensin systemleft ventricular hypertrophy 2Physical and Theoretical ChemistryCyclic guanosine monophosphate030304 developmental biology0303 health sciencesbiologyOrganic ChemistryAngiotensin-converting enzymehypotensivechemistryChemistry (miscellaneous)biology.proteinMolecular MedicineCreatine kinasehistopathology 6cardio relaxant 5Ex vivoMolecules
researchProduct

In reply-Angiotensin-Converting Enzyme 2 and the Resolution of Inflammation: In Support of Continuation of Prescribed Angiotensin-Converting Enzyme I…

2020

2019-20 coronavirus outbreakAngiotensinsCoronavirus disease 2019 (COVID-19)Pneumonia ViralAngiotensin-Converting EnzymeACE2InflammationAngiotensin-Converting Enzyme InhibitorsPharmacologyArticleAngiotensin Receptor AntagonistsBetacoronavirusRenin–angiotensin systemmedicineHumansPandemicsAntihypertensive AgentsInflammationAngiotensin Receptor Antagonistsbiologybusiness.industrySARS-CoV-2COVID-19Angiotensin-converting enzymeGeneral MedicineCoronavirusAngiotensin-converting enzyme 2biology.proteinAngiotensin Receptor BlockersAngiotensin-Converting Enzyme COVID-19 coronavirus ACE2medicine.symptombusinessCoronavirus InfectionsCoronavirus InfectionsMayo Clinic proceedings
researchProduct

ARIA���EAACI statement on asthma and COVID���19 (June 2, 2020)

2021

Artículo con numerosos autores sólo se mencionan el primero y el de la UAM

2019-20 coronavirus outbreakCoronavirus disease 2019 (COVID-19)AllergyStatement (logic)MedicinaSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)virusesImmunology610Settore MED/10 - Malattie Dell'Apparato Respiratoriomedicine.disease_cause03 medical and health sciences0302 clinical medicineastmaMedicine and Health SciencesmedicineHumansImmunology and Allergy030212 general & internal medicineLetters to the EditorLetter to the Editorudc:616.2AsthmaCoronavirusScience & Technologybusiness.industrySARS-CoV-2virus diseasesCOVID-19asthmamedicine.diseaseVirologyAsthma3. Good health030228 respiratory systemcovid-191107 ImmunologyAngiotensin-Converting Enzyme 2businessARIA-EAACILife Sciences & Biomedicine600 Technik Medizin angewandte Wissenschaften::610 Medizin und Gesundheit::610 Medizin und Gesundheit
researchProduct

Coronavirus disease 2019 infection and the cardiovascular system

2020

2019-20 coronavirus outbreakCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Pneumonia ViralAntiviral AgentsCardiovascular SystemSettore MED/11Renin-Angiotensin SystemBetacoronavirusPandemicHumansMedicinePandemicsHost Microbial InteractionsbiologySARS-CoV-2business.industryCOVID-19General Medicinebiology.organism_classificationmedicine.diseaseVirologyCOVID-19 Drug TreatmentPneumoniaCardiovascular DiseasesCoronavirus InfectionsCardiology and Cardiovascular MedicinebusinessBetacoronavirusJournal of Cardiovascular Medicine
researchProduct

Toxicity as prime selection criterion among SARS-active herbal medications

2021

We present here a new selection criterion for prioritizing research on efficacious drugs for the fight against COVID-19: the relative toxicity versus safety of herbal medications, which were effective against SARS in the 2002/2003 epidemic. We rank these medicines according to their toxicity versus safety as basis for preferential rapid research on their potential in the treatment of COVID-19. The data demonstrate that from toxicological information nothing speaks against immediate investigation on, followed by rapid implementation of Lonicera japonica, Morus alba, Forsythia suspensa, and Codonopsis spec. for treatment of COVID-19 patients. Glycyrrhiza spec. and Panax ginseng are ranked in …

2019-20 coronavirus outbreakmedicine.medical_specialtyRelative toxicityCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Pharmaceutical ScienceReviewSARS-CoV-2 severe acute respiratory syndrome coronavirus 203 medical and health sciencesCytochrome P450 Phytochemicals0302 clinical medicineSOD superoxide dismutaseDrug DiscoveryMedicineAnimalsHumansOral applicationIKK inhibitor of κB kinase030304 developmental biologyPharmacologyRational phytotherapy0303 health sciencesPublic healthCOVID-19 Coronavirus disease 2019JNK c-Jun N-terminale kinaseNO nitric oxidePlants MedicinalTraditional medicineToxicityACE2 angiotensin converting enzyme 2business.industrySARS-CoV-2Public healthCOVID-19Th2 T helper cells type 2NF-κB nuclear factor- κ B cellsComplementary and alternative medicine030220 oncology & carcinogenesisToxicityMolecular MedicineCYP cytochrome P450 monooxygenaseHIV-1 human immunodeficiency virus 1businessSelection criterionMAPK mitogen-activated protein kinaseDrugs Chinese HerbalPhytomedicine
researchProduct

In Reply – Association of Renin Angiotensin System Blockers with Outcomes in Patients With COVID-19

2020

2019-20 coronavirus outbreakmedicine.medical_specialtyhypertensionCoronavirus disease 2019 (COVID-19)business.industrySevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Renin-Angiotensin COVID-19 hypertensionCOVID-19General MedicineRenin-Angiotensin SystemBetacoronavirusInternal medicineRenin–angiotensin systemHumansMedicineIn patientCoronavirus InfectionsbusinessPandemicsRenin-AngiotensinLetter to the EditorMayo Clinic Proceedings
researchProduct

Cardiovascular and Renal Outcomes of Renin–Angiotensin System Blockade in Adult Patients with Diabetes Mellitus: A Systematic Review with Network Met…

2016

Background Medications aimed at inhibiting the renin–angiotensin system (RAS) have been used extensively for preventing cardiovascular and renal complications in patients with diabetes, but data that compare their clinical effectiveness are limited. We aimed to compare the effects of classes of RAS blockers on cardiovascular and renal outcomes in adults with diabetes. Methods and Findings Eligible trials were identified by electronic searches in PubMed/MEDLINE and the Cochrane Database of Systematic Reviews (1 January 2004 to 17 July 2014). Interventions of interest were angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), and direct renin (DR) inhibitors. T…

ACE inhibitorsMyocardial InfarctionAngiotensin-Converting Enzyme Inhibitors030204 cardiovascular system & hematologyACE inhibitor therapyBiochemistryRenin-Angiotensin SystemAnginachemistry.chemical_compoundEndocrinologyMathematical and Statistical Techniques0302 clinical medicineReninMedicine and Health SciencesSecondary Prevention030212 general & internal medicineMyocardial infarctionDiureticsStrokePharmaceuticsRDrugsEnzyme inhibitorsCardiovascular therapyGeneral Medicine3. Good healthHospitalizationStrokeNephrologyCardiovascular DiseasesPhysical SciencesCardiologyMedicineDrug therapyStatistics (Mathematics)Research Articlemedicine.drugAdultmedicine.medical_specialtyEndocrine DisordersCardiologyResearch and Analysis MethodsAngina PectorisDiabetes ComplicationsAngiotensin Receptor Antagonists03 medical and health sciencesDiabetes mellitusInternal medicineRenal DiseasesDiabetes MellitusmedicineHumansStatistical MethodsRenal Insufficiency ChronicPharmacologyHeart FailureCreatinineBiology and life sciencesbusiness.industryOdds ratiomedicine.diseasechemistryMetabolic DisordersHeart failuresistema cardiovascularACE inhibitorEnzymologyKidney Failure ChronicbusinessMathematicsMeta-AnalysisPLOS Medicine
researchProduct

cardiovascular effects of I/D angiotensin converting enzyme gene polymorphismin healty subjects: Findings after follow-up of six years

2005

Background - An increasing number of studies with conflicting results regarding the association between angiotensin-converting enzyme (ACE) gene deletion polymorphism and cardiovascular disease has recently been published. The present prospective long-term study was conducted to evaluate whether the DD genotype could also be associated with a higher prevalence of hypertension in healthy subjects over 6 years of follow-up. We also investigated the effects of the ACE-I/D genotypes on diastolic function by echocardiography in healthy subjects without any risk factors and any events after 6 years of follow-up. Methods - Population: 684 healthy volunteers (aged 25-55 years) normotensive and free…

ACE-I/D gene polymorphismDiastolic functionEchocardiographyHypertensionangiotensinHealthy subject
researchProduct

Coronavirus Disease 2019–Associated Coagulopathy

2021

Patients with the severe form of coronavirus disease 2019 (COVID-19) have been frequently found to suffer from both arterial and venous thrombotic events due to the perpetuation of a hypercoagulable state. This phenomenon, termed COVID-19-associated coagulopathy (CC), is now considered a major component of the pathophysiology of this novel infectious disease, leading to widespread thrombosis. While at first, the vascular insults may be limited to the pulmonary microvasculature, as the disease progresses, systemic involvement occurs, culminating in distant organ thrombosis and multi-organ dysfunction syndrome. In this review article, we discuss recent insights into the pathophysiologic mecha…

ARDSPAI-1 Plasminogen Activator Inhibitor 1VTE venous thromboembolismDiseaseReview030204 cardiovascular system & hematologyCoronavirus Disease 20190302 clinical medicineCoagulopathy030212 general & internal medicineDIC disseminated intravascular coagulationDisseminated intravascular coagulationCOVID-19 Coronavirus disease 2019DVT deep vein thrombosisGeneral MedicineBlood Coagulation DisordersThrombosisICU intensive care unitTMA thrombotic microangiopathyDisease ProgressionCoronavirus Disease 2019 COVID-19 CoagulopathyVWF von Willebrand factormedicine.medical_specialtyThrombotic microangiopathyACE2 angiotensin-converting enzyme 2SARS-CoV-2 severe acute respiratory syndrome coronavirus 203 medical and health sciencesmedicineCoagulopathyHumansIntensive care medicineLY30 lysis at 30 minutesARDS acute respiratory distress syndromeHemostasisNO nitric oxideCoagulationbusiness.industrySARS-CoV-2COVID-19Thrombosismedicine.diseasetPA tissue plasminogen activatorReview articleIL interleukinCoronavirusVascular DisorderPE pulmonary embolismTF tissue factorbusinessCC COVID-associated coagulopathyMayo Clinic Proceedings
researchProduct